The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population
Open accessAbstract
In health services planning, in addition to the basic measures of disease occurrence incidence and mortality, other indexes expressing the demand of care are also required to develop strategies for service provision. One of these is prevalence of the disease, which measures the absolute number, and relative proportion in the population, of individuals affected by the disease and that require some form of medical attention. For most cancer sites, cases surviving 5 years from diagnosis experience thereafter the same survival as the general population, so most of the workload is therefore due to medical acts within these first 5 years. This article reports world‐wide estimates of 1‐, 2–3‐ and 4–5‐year point prevalence in 1990 in the population aged 15 years or over, and hence describes the number of cancer cases diagnosed between 1986 and 1990 who were still alive at the end of 1990. These estimates of prevalence at 1, 2–3 and 4–5 years are applicable to the evaluation of initial treatment, clinical follow‐up and point of cure, respectively, for the majority of cancers. We describe the computational procedure and data sources utilised to obtain these figures and compare them with data published by 2 cancer registries. The highest prevalence of cancer is in North America with 1.5% of the population affected and diagnosed in the previous 5 years (about 0.5% of the population in years 4–5 and 2–3 of follow‐up and 0.4% within the first year of diagnosis). This corresponds to over 3.2 million individuals. Western Europe and Australia and New Zealand show very similar percentages with 1.2% and 1.1% of the population affected (about 3.9 and 0.2 million cases respectively). Japan and Eastern Europe form the next batch with 1.0% and 0.7%, followed by Latin America and the Caribbean (overall prevalence of 0.4%), and all remaining regions are around 0.2%. Cancer prevalence in developed countries is very similar in men and women, 1.1% of the sex‐specific population, while in developing countries the prevalence is some 25% greater in women than men, reflecting a preponderance of cancer sites with poor survival such as liver, oesophagus and stomach in males. The magnitude of disease incidence is the primary determinant of crude prevalence of cases diagnosed within 1 year so that differences by region mainly reflect variation in risk. In the long‐term period however different demographic patterns with long‐life expectancy in high‐income countries determine a higher prevalence in these areas even for relatively uncommon cancer sites such as the cervix. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,805
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Self-citationPisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<870::aid-ijc35>3.0.co;2-9 · Cited by 860
Self-citation(1995) · Cancer Causes and Control · doi:10.1007/bf00052188 · Cited by 477
Cancer Prevalence and Survivorship Issues: Analyses of the 1992 National Health Interview Survey
Hewitt, M., Breen, N., & Devesa, S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1480 · Cited by 207
Cancer survival in developing countries
Sankaranarayanan, R. (1998) · Cited by 187
Desai, M. M., BRUCE, M. L., Desai, R. A., & Druss, B. G. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.3.299 · Cited by 129
A method for the estimation of chronic disease morbidity and trends from mortality data
Verdecchia, A., Capocaccia, R., Egidi, V., et al. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080207 · Cited by 121
Merrill, R. M., Capocaccia, R., Feuer, E. J., & Mariotto, A. B. (2000) · International Journal of Epidemiology · doi:10.1093/ije/29.2.197 · Cited by 118
The prevalence of cancer among adults in the United States: 1987
Byrne, J., Kessler, L. G., & Devesa, S. S. (1992) · Cancer · doi:10.1002/1097-0142(19920415)69:8<2154::aid-cncr2820690823>3.0.co;2-r · Cited by 52
Cited by
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Self-citationCancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
Self-citationBade, B. C., & Dela Cruz, C. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.001 · Cited by 1,911
Global estimates of cancer prevalence for 27 sites in the adult population in 2008
Bray, F., Ren, J., Masuyer, E., & Ferlay, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.27711 · Cited by 1,891
Self-citationThe Biology and Life-Cycle of Human Papillomaviruses
Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., & Stanley, M. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.083 · Cited by 1,528
Metadata
- Authors
- Pisani, P., Bray, F., & Parkin, D. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001-10-04
- Volume
- 97
- Issue
- 1
- Pages
- 72-81
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2070152626
- Cited by
- 730
- References
- 10
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.